tirzepatide super obesity bmi 60 pharmacotherapy in older adults: a narrative review of evidence Disproportionate Increase in BMI of

For people with or without diabetes, this can sometimes lead to low blood sugar episodes (hypoglycemia), a major cause of dizzinessespecially when you havent eaten or after intense physical activity

Originally developed for Type 2 diabetes, these medications have gained FDA approval for obesity, reducing risk for heart disease and kidney disease, and treatment of obstructive sleep apnea within the last three years

Balanced optimism will help you navigate the emerging field of peptide therapy

For patients with type 2 diabetes, a 26-week phase II trial showed that 48% of participants achieved at least 10% weight reduction after treatment with orforglipron 45 mg

Clinical studies show tirzepatide users average 510 pounds per month during this phase, with continued appetite suppression and improved food choices becoming automatic

"We haven't had medications that could produce the weight losses that these (GLP-1s) are doing," said David B